• Explore /
  • Poster
  • / Activity of cabozantinib (CABO) plus durvalumab (DURVA) in patients (pts) with advanced urothelial carcinoma (UC) or non-UC variant histologies (VH) after platinum chemotherapy: Interim results from the phase 2 ARCADIA trial.

Activity of cabozantinib (CABO) plus durvalumab (DURVA) in patients (pts) with advanced urothelial carcinoma (UC) or non-UC variant histologies (VH) after platinum chemotherapy: Interim results from the phase 2 ARCADIA trial.

Abstract Poster

Authors

null

Patrizia Giannatempo

IRCCS Foundation National Cancer Institute, Milan, Italy

Patrizia Giannatempo , Valentina Guadalupi , Laura Marandino , Daniele Raggi , Marco Stellato , Alessandro Rametta , Giulia Baciarello , Achille Bottiglieri , Pierangela Sepe , Melanie Claps , Sebastiano Buti , Pipitone Stefania , Roberto Iacovelli , Giuseppina Calareso , Alessandra Alessi , Laura Cattaneo , Elena Verzoni , Giuseppe Procopio , Luigi Mariani , Andrea Necchi

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary Cancer—Kidney and Bladder

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Urothelial Cancer - Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT03824691

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 4578)

DOI

10.1200/JCO.2023.41.16_suppl.4578

Abstract #

4578

Poster Bd #

70

Abstract Disclosures

Similar Posters

First Author: Patrizia Giannatempo

First Author: Inkeun Park

First Author: Chee Khoon Lee

First Author: Geoffrey Thomas Gibney